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Abstract 
 
Patients with systemic sclerosis (SSc) experience significant morbidity and mortality, 
therefore, the development of tests to aid its early diagnosis are very important. The aim of 
this pilot study was to assess the diagnostic value of novel optical non-invasive skin 
fluorescence spectroscopy (FS) and tissue oxygen saturation (TOS) viability measurements in 
patients with established SSc. Two groups were studied, comprising 14 SSc patients and 9 
healthy controls (93% and 73% females, respectively). FS and TOS measurements were 
collected from 3 body sites: the forearm, chest, and calf. Fluorescence intensities at 
wavelengths attributed to collagen, elastin, and L-tryptophan were computed, with 
adjustment for melanin, and a normalised combined fluorescence score (NCFS) was 
determined. The NCFS was significantly higher (p<0.001) and the combined TOS 
significantly lower (p<0.001) in the SSc group. TOS measurements alone showed good 
classification accuracy (95.7%) at separating SSc from healthy control participants, with 
some clustering of values close to the 50% oxygenation level in both groups. When the 
composition and viability measures were combined and modelled using binary logistic 
regression, excellent results for the sample were obtained following leave one out cross 
validation (100%). The results of this pilot study demonstrate the potential diagnostic utility 
of FS and TOS assessments in SSc patients and further work is now needed to validate these 
techniques prospectively in a larger group of SSc patients across the spectrum of the disease, 
and also patients with other types of vasculopathy and conditions that can cause skin fibrosis.
  
 
Keywords: Systemic sclerosis, Biophotonics, Fluorescence spectroscopy, Tissue oxygen 
saturation, Connective Tissue Disease 
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Introduction 
 
Systemic sclerosis (SSc), also known as scleroderma, is a connective tissue disease with 
heterogeneous multi-system involvement, characterised by the presence of fibrosis, auto-
antibodies, and vasculopathy [1, 2]. Fibrosis is a hallmark of SSc and it leads to the 
replacement of the normal tissue architecture with stiff, collagen-rich connective tissue, 
resulting in skin thickening [3]. An early diagnosis would help implement the most 
appropriate treatment for each patient, i.e. the early initiation of immunosupressants and/or 
vasodilator drugs, as clinically indicated, thus improving quality of life and survival [4]. At 
the moment, however, there is a paucity of sensitive clinical tools for the early assessment of 
scleroderma. 
 
Nailfold capillaroscopy (NFC) is usually performed to investigate the presence of 
microangiopathy secondary to connective tissue disease, particularly in SSc [5]. This 
methodology, however, does not traditionally give a quantitative measure of abnormality for 
clinical use, despite some recent developments in this area [6, 7], and typically relies on the 
skills and experience of clinical specialists in the technique. Another  technique that has 
shown promise is optical coherence tomography (OCT), which can provide a virtual biopsy 
of the superficial layers of the skin [8, 9]. Other potentially useful and non-invasive 
alternatives to NFC and OCT are optical technologies such as fluorescence spectroscopy (FS) 
and tissue oxygen saturation (TOS). 
 
FS provides an “optical biopsy” of the skin [10, 11] and has been preliminary assessed in 
patients with diabetes [12-14] and systemic sclerosis [15, 16]. It can indirectly assess the 
amount of connective tissue (including collagen and elastin) in the measurement volume, as 
the higher the intensity, the higher the amount of fluorophore in the sample volume [17]. It is 
also sensitive to other key biomarkers such as L-tryptophan, and the relative fluorescence 
intensities between the various components can provide additional information. This 
technology would allow for the objective assessment of the changes in the composition of the 
connective tissue typical of SSc. TOS provides an objective assessment of tissue perfusion 
[18] and with microvascular perfusion characteristically impaired in patients with SSc [19], 
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this would provide valuable information regarding the viability of the superficial layers of 
tissue. 
 
The aim of this pilot study was to assess the clinical utility of novel optical non-invasive skin 
FS and TOS measurements to discriminate between healthy controls and patients with 
established SSc. 
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Methods 
 
Participants 
 
Two groups were studied in this pilot, comprising patients with SSc and healthy control (HC) 
participants. The SSc group fulfilled the American College of Rheumatology (ACR) 
preliminary classification criteria for systemic sclerosis [20]. The HC control group had no 
known major cardiovascular disease (hypertension, ischaemic heart disease, stroke, or 
peripheral vascular disease), no diabetes mellitus, no Raynaud’s phenomenon, and were not 
taking Vitamin D medication. All participants across both groups were of white Caucasian 
ethnic origin. The study was approved by a National Health Service (NHS) Research Ethics 
Committee (REC) (County Durham and Tees Valley 2, 07/Q1001/46), and all participants 
gave their written informed consent prior to participation in the study.  
 
Systolic and diastolic blood pressures were measured manually using a sphygmomanometer 
device (Accoson GreenlightTM 300, Harlow, UK). Height, weight, and cardiovascular history 
were also recorded for all of the participants. In the SSc group, their SSc clinical history, 
including disease duration (defined as the onset of the first non-Raynaud’s manifestation), 
sub-group (limited cutaneous [lcSSc] or diffuse cutaneous [dcSSc] disease), and modified 
Rodnan skin score (mRSS) were also documented [21, 22]. 
 
Vascular optical measurements 
 
The Freeman Hospital microvascular measurement protocol for subject preparation was 
followed [23]. This included no caffeine, nicotine, exercise, hot drinks, or substantial food in 
the four hours before measurements, as well as no cosmetic skin cream or talc to the hands, 
arms, or legs on the day of the test. Participants were given the opportunity to acclimatise in 
the normothermic (temperature 23.5±0.5°C, relative humidity 40-50%) temperature-
controlled measurement room for a period of at least 15 minutes prior to their measurements. 
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FS and TOS measurements were made by a single operator (JA) at three body sites: the 
forearm (over the dorsal aspect, 3 cm proximal of the wrist on the non-dominant arm); the 
chest; and the calf (over the lateral aspect of leg, 12 cm proximal of the ankle joint on the 
non-dominant leg). Measurements were made in minimal ambient lighting conditions to 
reduce the risk of interference. 
 
Tissue fluorescence for tissue composition 
 
A FS system (SPEX-2 Fluoromax, Horiba Jobin-Yvon, Stanmore, UK) was used to measure 
the skin tissue fluorescence excitation-emission characteristics. The study wavelengths 
comprised an excitation range of 260-500 nm and corresponding emission range of 290-750 
nm. This range includes the three key regions relative to collagen (C) type I (located at 
wavelengths of 340 nm excitation and 390 nm emission), elastin (E) (370 nm excitation, 440 
nm emission), and L-tryptophan (T) (290 nm excitation, 350 nm emission) [24, 25]. The 
excitation and emission spectra were processed to form an excitation-emission matrix (EEM) 
[11], from which specific fluorophore intensities were extracted using MATLAB software 
developed in-house by JA (The Mathworks Inc., Natick, MA, USA). Fluorescence intensities 
were measured as counts of photons per second (cps). Figure 1 shows an example EEM with 
the three fluorophore wavelength areas indicated. 
 
Fluorescence assessments are biased by skin colour, and in order to compensate for this, a 
colorimeter (Konica Minolta type CM-508i, Warrington, UK) was used to objectively 
quantify skin colour from reflectance data. The key compound affecting skin colour is 
melanin which exhibits a reflectance peak at 660 nm [26]. This information was extracted to 
form a Melanin Index (MI) which corrected the values returned by FS. The Melanin Index 
was computed as described in equation 1 [27]. 
 
MI (in %) = 100 x log10 (100 / reflectance at 660 nm)   (1) 
 
Fluorescence cps were multiplied by MI/100 to give melanin normalised TMI, CMI and EMI 
values at each body site. These values were then combined across the three body sites for 
each of the three fluorophores as a summation, with the example of collagen described in 
equation 2. 
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CMI combined = CMI  forearm + CMI  chest + CMI calf  (2) 
 
A normalised combined fluorescence score (NCFS) for connective tissue was then calculated 
as described in equation 3 to give a dimensionless index for each participant. 
 
NCFS = (CMI combined + EMI combined) / TMI combined    (3) 
 
 
Figure 1 - Example fluorescence spectroscopy (FS) excitation-emission matrix (EEM) for a 
single body skin measurement site. The black squares indicate the foci from where the three 
key wavelength regions from which L-tryptophan, collagen (type I), and elastin fluorophore 
intensities were extracted. The fluorescence intensity scale in counts per second (cps) is 
added vertically to the right hand side of the figure. 
 
Tissue oxygen saturation for tissue viability 
 
TOS [28, 29] was measured using an O2C system (LEA Medizintechnik GmBH type O2C, 
Giessen, Germany) using a LMF-2 flat skin probe. Although the specific algorithm used by 
the device is proprietary to LEA, the technique is based on deriving the superficial TOS from 
the profile of the reflection spectra across a range of visible wavelengths close to green. The 
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TOS values from each participant were combined across their three body sites using a simple 
mean representation. 
 
Statistical analysis 
 
Demographic, clinical, and optical measurements were summarised for each participant 
group using non-parametric descriptive statistics, i.e. median [inter-quartile range] values. 
The differences between participant groups in numerical measures were assessed for 
statistical significance using the Mann-Whitney U-test, and binary categorical counts using 
the Fisher’s exact test. A significance level of 95% was considered statistically significant. A 
classification model (SSc vs HC) was produced using binary logistic regression (BLR), with 
NCFS and the mean TOS used as predictors [30]. To investigate the model stability and 
generalisability outwith the current sample, leave one out cross validation (LOOCV) was 
used. The LOOCV adjusted predicted probabilities for a participant having SSc, returned 
from the BLR models, were used to develop a novel diagnostic disease probability plot, with 
linear interpolation used to smooth boundaries. Receiver operating characteristic (ROC) 
analysis was performed to assess the diagnostic performance of the model using the LOOCV 
adjusted predicted probabilities. All statistical analyses and plots were produced using the 
statistical programming language R (version 3.1.1), via the integrated development 
environment RStudio (version 0.99.446). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 8 of 21AUTHOR SUBMITTED MANUSCRIPT - PMEA-102237.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 Ac
ce
pte
d M
nu
scr
i t
SScFl paper v5 010218 
9 
 
 
 
 
Results 
 
Demographic and clinical characteristics 
 
A summary of the demographics and clinical characteristics for the 14 SSc and 9 HC 
participants are presented in Table 1. There were no significant differences between the two 
groups across all demographics and clinical characteristics, although significance was almost 
reached in age (61 years [54-64] versus 52 [48-55]) and diastolic blood pressure (70 mmHg 
[61-86] versus 78 [72-78]). 
 
Table 1 – Summary of demographics and clinical characteristic of the systemic sclerosis (SSc) 
and healthy control (HC) groups. 
 
 
 SSc (n = 14)  HC (n  = 9)  
  Median 
(n) 
[IQR] or 
(%)  
 Median 
(n) 
[IQR] or 
(%) 
p value 
Female (n)  (13) (93)  (7) (78) 0.53 
Age (years)  61 [54-64]  52 [48-55] 0.07 
SBP (mmHg)  112 [106-125]  122 [112-124] 0.47 
DBP (mmHg)  70 [61-75]  78 [72-78] 0.05 
Height (m)  1.64 [1.61-1.68]  1.67 [1.66-1.73] 0.16 
Weight (kg)  70 [61-86]  66 [66-82] 0.95 
BMI (kg/m2)   26.1 [22.9-30.5]  24.0 [23.1-26.2] 0.47 
Current smokers (n)  (0) (0)  (1) (11) No comp 
Diabetes (n)  (2) (17)  (0) (0) No comp 
‘SBP’ = ‘Systolic blood pressure’; ‘DBP’ = ‘Diastolic blood pressure’; ‘No comp’ = ‘No comparison from 
Fisher’s exact test possible’ 
 
 
In the SSc group, patients had a median [IQR] mRSS of 7 [4-15], an SSc duration (in years) 
of 6 [3-8], with 7 patients (50%) having limited SSc, and 7 patients (50%) having diffuse 
SSc. 11 patients (79%) also had positive immunology identified by anti-centromere antibody 
(4 patients), anti-topoisomerase I (2 patients), RNA polymerase III (1 patient), and anti-
nuclear antibody (4 patients). Six patients with SSc had interstitial lung disease (ILD). 
 
Tissue fluorescence - composition 
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Melanin 
In the SSc group, the median [IQR] melanin index at the forearm was 28.9% [26.4-31.2], 
chest 32.8% [29.1-39.3], and calf 26.0% [23.5-26.8]. In the HC group, the median [IQR] 
melanin index at the forearm was 28.4% (26.9-31.0), chest 27.2% (26.1-32.2), and calf 25.2% 
(24.4-27.2). The melanin indices were used to adjust the L-tryptophan, collagen, and elastin 
fluorophores for tissue pigmentation. 
 
Fluorophores – melanin normalised 
Table 2 presents a comparison of the melanin normalised tissue fluorescence values for TMI, 
CMI, and EMI across the body sites and between the SSc and HC groups. 
 
Table 2 – Comparison of the melanin normalised tissue fluorescence values (k counts of 
photons per second (cps)) for L-tryptophan (TMI), collagen (CMI), and elastin (EMI), across the 
body sites of the forearm, chest, calf, combined sites, and the normalised combined 
fluorescence score (NCFS) between the systemic sclerosis (SSc) and healthy control (HC) 
groups. 
 
 SSc (n = 14)  HC (n  = 9)   
  Median [IQR]  Median [IQR]  p value 
L-tryptophan (TMI)         
  -Forearm   96 [59-133]  71 [52-92]  0.602 
  -Chest   17 [11-25]  9 [7-31]  0.688 
  -Calf   163 [130-216]  307 [271-319]  0.004*  
  -Combined (sum)  269 [234-370]  373 [354-458]  0.062 
Collagen (CMI)         
  -Forearm   146 [122-175]  95.7 [86-111]  0.062 
  -Chest   171 [107-248]  74.3 [50-126]  0.045* 
  -Calf   283 [188-336]  296 [248-440]  0.403 
  -Combined (sum)  610 [464-738]  473 [420-682]  0.369 
Elastin (EMI)         
  -Forearm   327 [296-407]  237 [198-255]  0.016* 
  -Chest   388 [278-610]  157 [104-260]  0.009* 
  -Calf   530 [402-652]  474 [360-646]  0.734 
  -Combined (sum)  1302 [1061-1530]  851 [771-1126]  0.023 
NCFS  6.49 [5.53-9.76]  3.53 [2.92-4.52]  < 0.001* 
* = significant at the 0.05 level 
 
 
When the body sites were combined, there were no significant differences in TMI and CMI (p = 
0.062 and p = 0.369, respectively) between SSc patients and HCs. There was a significant 
difference in EMI between groups (p = 0.023), with SSc patients having greater EMI levels 
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than healthy controls (1302 [1061-1530] versus 851 [771-1126]. There was also a significant 
difference in NCFS between the groups, with SSc patients having a greater NCFS than HCs 
(6.49 [5.53-9.76] versus 3.53 [2.92-4.52]). 
 
Tissue oxygen saturation - viability 
 
Table 3 presents a comparison of TOS across the body sites and between the SSc and HC 
groups. A combined tissue oxygen value for the 3 sites is also quantified and compared. 
 
There were significant differences between participant groups in the TOS at the forearm, 
chest, and calf, and then when combined (p<0.001, p=0.029, p<0.001, p<0.001, respectively), 
with SSc patients having significantly reduced TOS than HCs (Table 2).  
 
Table 3 – Comparison of tissue oxygen saturation (TOS) across the body sites of the forearm, 
chest, calf, and combined sites between the systemic sclerosis (SSc) and healthy control (HC) 
groups. 
 
 
 SSc (n = 14)  HC (n  = 9)   
  Median [IQR]  Median [IQR]  p value 
  -Forearm (%)  37 [32-46]  58 [57-61]  < 0.001* 
  -Chest (%)  56 [49-61]  70 [56-73]  0.029 
  -Calf (%)  26 [21-31]  49 [44-66]  < 0.001*  
  -Combined (%) 
(mean TOS) 
 
 
42 
 
[36-45] 
  
56 
 
[54-66] 
  
< 0.001* 
* = significant at the 0.05 level 
 
 
Combined fluorescence spectroscopy and tissue oxygen saturation assessments 
 
Figure 2 depicts a disease probability plot displaying the LOOCV adjusted predicted 
probability for a participant having SSc returned from a BLR model (Group ~ NCFS + Mean 
TOS).  
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Figure 2 – Novel diagnostic disease probability plot displaying the leave 
one out cross validation (LOOCV) adjusted predicted probability for a 
participant having systemic sclerosis (SSc) returned from a binary 
logistic regression (BLR) model (SSc/HC ~ NCFS + Mean tissue oxygen 
saturation (TOS)). 
 
 
Figure 3 presents the diagnostic performance of the BLR model using LOOCV adjusted 
predicted probabilities for a participant having SSc. The optimal LOOCV adjusted predicted 
probability threshold was 0.956 (Figure 3). At this threshold, the accuracy, sensitivity, 
specificity, negative predictive value (PPV), and positive predictive value (PPV) of the model 
were all 100%.  
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Figure 3 – Receiver operating characteristic (ROC) curves displaying the diagnostic 
performance of the binary logistic regression (BLR) models, using leave one out cross 
validation (LOOCV) adjusted predicted probabilities, for a participant having systemic 
sclerosis (SSc) using the following predictors: I – normalised combined fluorescence score 
(NCFS) and mean tissue oxygen saturation (TOS); II – NCFS; III – TOS. The optimal 
LOOCV adjusted predicted probability threshold (specificity, sensitivity) and area under the 
curve (AUC) values (95% confidence interval) are shown. 
 
 
For NCFS used alone, the optimal LOOCV adjusted predicted probability threshold was 
0.726. At this threshold, the accuracy of the model was 91.3%, sensitivity 85.7%, specificity 
100%, PPV 100%, and NPV 81.8%. For TOS used alone, the optimal LOOCV adjusted 
predicted probability threshold was 0.992. At this threshold, the accuracy of the model was 
95.7%, sensitivity 92.9.7%, specificity 100%, PPV 100%, and NPV 99.2%. 
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Discussion and Summary 
 
Our pilot study, using a non-invasive combined fluorescence score (NCFS) and TOS 
measurements over 3 different skin sites on the body, has shown that in SSc there is 
significantly increased fluorescence associated with connective tissue whilst tissue 
oxygenation levels are significantly reduced. TOS measurements alone showed good 
classification accuracy, after cross validation (95.7%), for separating SSc patients from HCs, 
although there was some clustering of values close to the 50% oxygenation level in both 
groups. When the composition and viability measures were combined and compared using a 
BLR classification model, excellent classification accuracy after cross validation was 
observed (100%). The results of this pilot study demonstrate the potential diagnostic utility of 
FS and TOS assessments in SSc patients, and further work is needed to validate these 
techniques prospectively in a larger group of SSc patients and also patients with other 
conditions that can cause skin fibrosis. 
 
Another previous study that assessed tissue FS in patients with systemic sclerosis reported 
significant differences in fluorescence at some sites along the arm, although with overlap in 
measurements between the participant groups [16]. In this study, we have made advances to 
the method in various ways: developing the combined fluorescence score (NCFS) which 
represents measurements from 3 skin sites across the body to give a wider picture of tissue 
composition changes, including an adjustment for tissue melanin since skin pigmentation is 
known to change in patients with SSc; exploring the value of combining FS with TOS 
measurements to enhance the diagnostic accuracy; and introducing a novel disease 
probability plot to aid the visual interpretation of the two measurements. 
 
The results of increased connective tissue in SSc patients, i.e. collagen and elastin, are 
consistent with the well-known presence of fibrosis in these patients; as microvascular 
oxygenation is characteristically impaired in patients with SSc. Resulting hypoxia can lead to 
an increase in collagen production by the fibroblasts with altered transforming growth factor 
beta (TGFβ) function a key factor in the increased fibrosis. TGFβ is pleiotropic and as well as 
stimulating fibroblasts to stimulate collagen synthesis, it also stimulates the synthesis of 
elastin [31, 32]. We have looked at two pathways both of which are important in the 
pathogenesis of SSc, i.e. vascular and fibrosis. A third possible pathway to explore would be 
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immunological markers, with our method having the potential to improve classification in 
those who have SSc but with non-specific or negative immunology. In this study, only half of 
the SSc patients had specific immunological markers associated with the condition, although 
nonspecific antibodies were present in other patients. 
 
Interestingly, neither fluorescence nor TOS correlated significantly with the validated mRSS 
which evaluates skin thickness, which will need to be explored further. The method will also 
need to be assessed in a larger cohort of patients with SSc, including patients with newly 
diagnosed disease, although some patients with early SSc were included in this study. The 
novel diagnostic disease probability plot (Figure 2) also needs to be tested prospectively, and 
if the same level of diagnostic performance were to be maintained in patients with early 
phase SSc, this would be very beneficial and facilitate early treatment with 
immunosupressants and/or vasodilator drugs as clinically indicated. However, this needs to 
be tested in a wider study of early, active, and late phase SSc patients. Other patient groups 
should also be tested, including patients with primary Raynaud’s phenomenon and patients 
with pre-scleroderma, i.e. patients that have Raynaud’s and the specific antibodies seen in 
SSc, but who have no other clinical features of SSc. Following this group longitudinally and 
seeing if these measurements could predict who will develop SSc would also be interesting 
and of potential clinical importance. In addition, a further study should include a wider cohort 
to allow the assessment of non-Caucasian participants, a range of vascular pathologies 
including arteriosclerosis and a range of patients with diabetes, as well as participants with 
calcinosis and interstitial lung disease (ILD) using the two optical techniques [33]. Additional 
clinical information, such as the hormonal activity of female participants, should also be 
captured due to the potential effect of the menstrual cycle on results. Other techniques, such 
as OCT [8, 9] should also be considered to help investigate the utility of biophotonic 
techniques for SSc assessments. 
 
FS and TOS measurements are efficient, requiring only a few minutes per body site and could 
be made faster and lower cost with the latest technology options in FS and TOS using 
spectrophotometry. The technologies are safe and pose no risk to the patient when the correct 
optical procedures are followed. The techniques offer potential value in SSc diagnostics, 
screening, monitoring response to treatment, and may complement existing validated 
methods such as nailfold capillaroscopy. In summary, in this pilot study, the normative 
ranges for the combined fluorescence score (NCFS) and TOS have been estimated for the 
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three body measurement sites and provided high diagnostic classification accuracies for SSc 
patients. A further larger study is required to validate these findings.  
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